Aytu BioPharma マネジメント
マネジメント 基準チェック /34
Aytu BioPharmaの CEO はJosh Disbrowで、 Apr2015年に任命され、 の在任期間は 11.25年です。 の年間総報酬は$ 883.93Kで、 66.7%給与と33.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.93%を直接所有しており、その価値は$ 426.84K 。経営陣と取締役会の平均在任期間はそれぞれ3.7年と10年です。
主要情報
Josh Disbrow
最高経営責任者
US$883.9k
報酬総額
| CEO給与比率 | 66.75% |
| CEO在任期間 | 11.3yrs |
| CEOの所有権 | 1.9% |
| 経営陣の平均在職期間 | 3.7yrs |
| 取締役会の平均在任期間 | 10yrs |
経営陣の近況
分析記事 • May 14
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...分析記事 • Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...Recent updates
ナラティブ更新 • Jun 26
AYTU: Higher Margins And Lower P/E Will Support Future Upside
Aytu BioPharma’s analyst price target has shifted from $12.50 to $14.50, with analysts pointing to updated assumptions for higher revenue growth, stronger profit margins, and a lower future P/E multiple as key drivers of the new outlook. What's in the News No recent company specific news items were identified for Aytu BioPharma from the provided sources.分析記事 • Dec 20
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...分析記事 • Nov 17
Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...分析記事 • Oct 30
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price Rise
Those holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...分析記事 • Jul 29
Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...分析記事 • May 14
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...分析記事 • May 04
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...分析記事 • Jan 18
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...分析記事 • Nov 15
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...分析記事 • Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...分析記事 • Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...分析記事 • Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...分析記事 • Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...Seeking Alpha • Oct 13
Aytu stock falls amid suspending clinical programs to save costs
Aytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.Seeking Alpha • Sep 27
Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.Seeking Alpha • Sep 14
Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.Seeking Alpha • Aug 16
Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16Seeking Alpha • Aug 09
Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.分析記事 • May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...分析記事 • Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$34m |
| Dec 31 2025 | n/a | n/a | -US$25m |
| Sep 30 2025 | n/a | n/a | -US$13m |
| Jun 30 2025 | US$884k | US$590k | -US$14m |
| Mar 31 2025 | n/a | n/a | US$2m |
| Dec 31 2024 | n/a | n/a | -US$4m |
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | US$928k | US$590k | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$12m |
| Dec 31 2023 | n/a | n/a | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | US$708k | US$590k | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | n/a | n/a | -US$77m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | US$590k | US$590k | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | US$6m | US$545k | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | US$2m | US$608k | -US$14m |
報酬と市場: Joshの 総報酬 ($USD 883.93K ) は、 US市場 ($USD 663.17K ) の同規模の企業の平均を上回っています。
報酬と収益: Joshの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Josh Disbrow (51 yo)
11.3yrs
在職期間
US$883,928
報酬
Mr. Joshua R. Disbrow, also known as Josh, serves as Chief Executive Officer at Aytu Biopharma, Inc. since April 16, 2015 and served as its Chairman until 2024. He served as President at Aytu Biopharma, In...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 11.3yrs | US$883.93k | 1.93% $ 426.8k | |
| CFO, Corporate Secretary & Treasurer | 1.7yrs | US$538.65k | 0.46% $ 102.5k | |
| Chief Business Officer | 3.7yrs | US$549.25k | 0.57% $ 126.8k | |
| Chief Commercial Officer | 4.5yrs | US$522.08k | 0.34% $ 74.4k | |
| Vice President of Operations | no data | データなし | データなし | |
| Senior Vice President of Scientific Affairs | 1.1yrs | データなし | データなし |
3.7yrs
平均在職期間
49yo
平均年齢
経験豊富な経営陣: AYTUの経営陣は 経験豊富 であると考えられます ( 3.7年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 10.5yrs | US$883.93k | 1.93% $ 426.8k | |
| Independent Director | 4yrs | US$87.76k | 0.18% $ 40.8k | |
| Independent Chairman | 10yrs | US$117.76k | 0.13% $ 28.4k | |
| Independent Director | 10.3yrs | US$82.76k | 0.20% $ 43.6k | |
| Independent Director | 3.1yrs | US$77.76k | 0.18% $ 40.2k |
10.0yrs
平均在職期間
59yo
平均年齢
経験豊富なボード: AYTUの 取締役会 は経験豊富で 経験豊富 です ( 10年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/28 08:07 |
| 終値 | 2026/07/28 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Aytu BioPharma, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Thomas Flaten | Lake Street Capital Markets, LLC |